{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-21-002921","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2021-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.316917+00:00","generated_at":"2026-06-30T05:37:29.457557+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PharmaCyte Biotech effects 1-for-1,500 reverse stock split, reduces outstanding shares to ~1.6M","bullets":["Reverse stock split ratio 1:1,500; outstanding shares reduced from ~2.4B to ~1.6M.","Authorized shares decreased from 50B to 33,333,334; par value unchanged at $0.0001.","Effective July 12, 2021; temporary ticker PMCBD for 20 business days, then revert to PMCB.","CEO states split is a necessary step before Nasdaq listing and to support financing.","No fractional shares issued; proportionate voting power unaffected; rounding up to whole share."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-21-002921","json":"https://secwatch.observer/filing/0001683168-21-002921.json","markdown":"https://secwatch.observer/filing/0001683168-21-002921.md","text":"https://secwatch.observer/filing/0001683168-21-002921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/0001683168-21-002921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T05:37:29.457557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}